Primary anaplastic large cell lymphoma of skeletal muscle presenting with compartment syndrome.

Abstract:

:We describe a patient with primary anaplastic large cell lymphoma of the forearm presenting with compartment syndrome. Urgent decompression fasciotomy and combination chemotherapy resulted in durable remission status. This is followed by a review of primary skeletal muscle lymphoma in the English literature.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Chim CS,Choy C,Liang R

doi

10.3109/10428199909058467

keywords:

subject

Has Abstract

pub_date

1999-05-01 00:00:00

pages

601-5

issue

5-6

eissn

1042-8194

issn

1029-2403

journal_volume

33

pub_type

杂志文章
  • The role of aberrant transcription factor in the progression of chronic myeloid leukemia.

    abstract::Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease with distinct biological and clinical features. The Philadelphia (Ph) chromosome and BCR/ABL fusion gene is the major cytogenetic and molecular marker of CML chronic phase. However, the molecular mechanisms of disease progression are not well known. R...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190802163305

    authors: Zhang S

    更新日期:2008-08-01 00:00:00

  • Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide.

    abstract::Fludarabine is an active agent for the treatment of Waldenstrom's macroglobulinemia (WM) and its combination with cyclophosphamide has been effective in many patients with low-grade lymphoma and chronic lymphocytic leukemia. Based on these data, we administered the combination of fludarabine (25 mg/m2 i.v. day 1-3) an...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/1042819031000077025

    authors: Dimopoulos MA,Hamilos G,Efstathiou E,Siapkaras I,Matsouka C,Gika D,Grigoraki V,Papadimitriou C,Mitsibounas D,Anagnostopoulos N

    更新日期:2003-06-01 00:00:00

  • Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells.

    abstract::Bone marrow mesenchymal stromal cells (MSCs) can rescue acute lymphoblastic leukemia (ALL) cells from L-asparaginase by replenishing the depleted asparagine. As both vincristine (VCR) and imatinib mesylate (IM) can inhibit MSCs' proliferation, we hypothesized that these drugs might reduce the niche support of MSCs to ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190903406798

    authors: Fung KL,Liang RH,Chan GC

    更新日期:2010-03-01 00:00:00

  • Multiple myeloma associated with lactic acidosis.

    abstract::Type B lactic acidosis is rare among patients with malignant diseases. To date only one case report has documented lactic acidosis occurring in a patient with multiple myeloma (MM). Our patient, a 55-year-old black man, was diagnosed with stage IIIA immunoglobulin G-kappa (IgG-kappa) MM in September 1995. He was found...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000040116

    authors: Ustun C,Fall P,Szerlip HM,Jillella A,Hendricks L,Burgess R,Dainer P

    更新日期:2002-12-01 00:00:00

  • Complex IgA gammopathy in Gaucher's disease.

    abstract::A 55-year-old Jewish patient was simultaneously diagnosed as having Gaucher's disease and IgA multiple myeloma. Serum protein electrophoresis and immunoelectrophoresis showed two different IgA kappa type monoclonal spikes. After four years of observation, a rapid fatal course of disease developed together with express...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509054770

    authors: Shvidel L,Hurwitz N,Shtalrid M,Zur S,Oliver O,Berrebi A

    更新日期:1995-12-01 00:00:00

  • Acute myeloid leukemia and the infectious diseases consultant.

    abstract::Infectious complications following treatment of acute myeloid leukemia (AML) are important causes of morbidity and mortality. The spectrum and complexity of these infections is reflected by the severe net state of immunosuppression of AML patients, that is dynamic and continuously changing, the polypharmacy, including...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1365861

    authors: Mulanovich V,Kontoyiannis DP

    更新日期:2018-06-01 00:00:00

  • Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group.

    abstract::This retrospective study concerns non-bacterial infections in Asian patients receiving alemtuzumab. The clinical data of 182 patients treated with alemtuzumab alone or alemtuzumab-containing chemotherapy between the years 2003 and 2009 was collected from six Asian countries. Alemtuzumab was used in the setting of fron...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.659735

    authors: Kim SJ,Moon JH,Kim H,Kim JS,Hwang YY,Intragumtornchai T,Issaragrisil S,Kwak JY,Lee JJ,Won JH,Reksodiputro AH,Lim ST,Cheng AL,Kim WS,Kwong YL

    更新日期:2012-08-01 00:00:00

  • Neurological presentation of Hodgkin lymphoma in the Italian Association of Pediatric Hematology and Oncology LH-2004 protocol.

    abstract::Neurological symptoms can represent the first clinical manifestation of central nervous system (CNS) involvement in Hodgkin lymphoma (HL). Because of its rarity, it is often misunderstood for other pathological processes. We report two cases of pediatric CNS HL, presenting with neurological symptoms at diagnosis. We h...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.562573

    authors: Burnelli R,Fabbri E,Guerrini G,Sperlì D,D'ambrosio A

    更新日期:2011-06-01 00:00:00

  • B cell chronic lymphocytic leukemia with florid reactive CD4+ T cell lymphocytosis in lymph nodes.

    abstract::This case is of an unusual florid reactive CD4+ T Cell lymphocytosis involving lymph node (LN) and overshadowing residual B chronic lymphocytic leukemia (CLL). A 65 year old female with a 9 year history of untreated B-CLL presented with weight loss, splenomegaly and lymphadenopathy. B-CLL was confirmed on the basis of...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309148519

    authors: Busmanis I,Hussein S,Feleppa F,Rockman S,Begley CG

    更新日期:1993-01-01 00:00:00

  • Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia.

    abstract::Myocyte enhancer factor 2C (MEF2C) encodes a transcription factor which is ectopically expressed in T-cell acute lymphoblastic leukemia (T-ALL) cell lines, deregulated directly by ectopically expressed homeodomain protein NKX2-5 or by loss of promoter regions via del(5)(q14). Here, we analyzed the MEF2C 5'-region, thu...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.537003

    authors: Nagel S,Venturini L,Meyer C,Kaufmann M,Scherr M,Drexler HG,Macleod RA

    更新日期:2011-02-01 00:00:00

  • The serum levels of eosinophil cationic protein (ECP) are related to the infiltration of eosinophils in the tumours of patients with Hodgkin's disease.

    abstract::We have previously described a relation between abundance of eosinophilic granulocytes in Hodgkin's disease (HD) tumours and poor prognosis. In order to further explore the importance of the eosinophilic infiltration, we immunohistochemically examined the presence of eosinophils, using the monoclonal antibodies EG 1 a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109064602

    authors: Molin D,Glimelius B,Sundström C,Venge P,Enblad G

    更新日期:2001-07-01 00:00:00

  • Skewing of the T-cell receptor repertoire in patients receiving rituximab after allogeneic hematopoietic cell transplantation: what lies beneath?

    abstract::Rituximab is known to affect T cell immune responses. We and others have reported expansions of T large granular lymphocytes (T-LGLs) in lymphoma patients after Rituximab. We report here the immunogenetic profiling of the T cell receptor (TR) gene repertoire in 14 patients who received Rituximab post allo-HCT and expl...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1543881

    authors: Papalexandri A,Karypidou M,Stalika E,Kotta K,Touloumenidou T,Zerva P,Paleta A,Mallouri D,Batsis I,Sakellari I,Kotsianidis I,Anagnostopoulos A,Hadzidimitriou A,Margaritis D,Stamatopoulos K

    更新日期:2019-07-01 00:00:00

  • Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy.

    abstract::Along with the establishment of more intense chemotherapeutic regimens including fludarabine for the treatment of indolent lymphoproliferative diseases like chronic lymphocytic leukemia (CLL), an increasing amount of cases with progressive multifocal leukoencephalopathy (PML) due to JC virus have been observed. We rep...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819031000116625

    authors: Kiewe P,Seyfert S,Körper S,Rieger K,Thiel E,Knauf W

    更新日期:2003-10-01 00:00:00

  • Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.

    abstract::We aimed to identify whether the use of autologous hematopoietic cell transplantation (HCT) impacts outcomes for multiple myeloma patients with gains of chromosome 1q (+1q). We retrospectively identified 95 patients, 21% having +1q. For patients with +1q, the overall response rate to induction was 85%, with 40% having...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1260126

    authors: Shah GL,Landau H,Londono D,Devlin SM,Kosuri S,Lesokhin AM,Lendvai N,Hassoun H,Chung DJ,Koehne G,Jhanwar SC,Landgren O,Levine R,Giralt SA

    更新日期:2017-08-01 00:00:00

  • Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression.

    abstract::Recent data have suggested that rituximab is an active agent for the treatment of Waldenstrom's macroglobulinemia (WM). However, the patients that are more likely to benefit have not been clearly defined. In order to address this question we evaluated 52 patients who were treated with single-agent rituximab in the con...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/10428190410001723287

    authors: Dimopoulos MA,Alexanian R,Gika D,Anagnostopoulos A,Zervas C,Zomas A,Kyrtsonis MC,Anagnostopoulos N,Pangalis GA,Weber DM

    更新日期:2004-10-01 00:00:00

  • Non-Hodgkin's lymphoma and pregnancy.

    abstract::Non-Hodgkin's lymphoma (NHL) is infrequently diagnosed during pregnancy. Most NHL's complicating pregnancy are aggressive and disseminated. This presentation together with the possible teratogenecity of diagnostic methods dictate a limited staging workup during pregnancy. Although prognosis had been reported to be poo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199409049697

    authors: Lishner M,Zemlickis D,Sutcliffe SB,Koren G

    更新日期:1994-08-01 00:00:00

  • Primary hematolymphoid malignancies involving the extrahepatic bile duct or gallbladder.

    abstract::Primary hematolymphoid malignancies of the extrahepatic biliary tract are rare tumors. We report five cases of primary hematolymphoid malignancies involving the extrahepatic biliary tract. One is a granulocytic sarcoma of the extrahepatic bile duct, another is an extramedullary plasmacytoma of the gallbladder, and the...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.483300

    authors: Hwang DW,Lim CS,Jang JY,Lee SE,Yoon SO,Jeon YK,Uk Lee K,Kim SW

    更新日期:2010-07-01 00:00:00

  • BCR-ABL directed immunotherapy: a virtual reality?

    abstract::Nearly ten years of research on the feasibility of specific immunotherapy targeting the junctional regions of BCR-ABL has considerably increased our knowledge of which MHC alleles might present BCR-ABL peptides, yet has failed to provide us with definite proof of appropriate processing of the hybrid oncoprotein into s...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190009060331

    authors: Leeksma OC,Kessler JH,Huijbers IJ,Ten Bosch GJ,Melief CJ

    更新日期:2000-06-01 00:00:00

  • Bone marrow aplasia with prominent atypical plasmacytic proliferation preceding acute lymphoblastic leukemia.

    abstract::A two-year-old boy presented with pancytopenia. Bone marrow examination revealed an aplastic marrow with prominent immature plasma cell proliferation, which mimicked plasma cell leukemia. Immunohistochemistry, however, revealed a polyclonal population consistent with a reactive process, excluding plasma cell neoplasia...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909145722

    authors: Kikuchi M,Ohsaka A,Chiba Y,Sato M,Muraosa Y,Hoshino H

    更新日期:1999-09-01 00:00:00

  • Fish demonstrates treatment-related chromosome damage in myeloid but not plasma cells in primary systemic amyloidosis.

    abstract::Conventional cytogenetic analysis is limited in the evaluation of plasma cell disorders because, relative to normal hematopoietic elements, plasma cells divide slowly. Moreover, it is difficult to know whether abnormal metaphases originate from malignant plasma cells or myeloid cells harboring other abnormalities. We ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009065839

    authors: Fonseca R,Rajkumar SV,Ahmann GJ,Jalal SM,Hoyer JD,Gertz MA,Kyle RA,Greipp PR,Dewald GW

    更新日期:2000-10-01 00:00:00

  • Thymidylate synthase polymorphisms and hematological cancer risk: a meta-analysis.

    abstract::Previous studies on the association of Thymidylate synthase (TYMS) polymorphisms with risk of hematological malignancies have produced conflicting results. The purpose of this meta-analysis was to define the effect of TYMS 5'-untranslated enhanced region (TSER) and 3'-untranslated region (TS3'-UTR) polymorphisms on th...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2011.649477

    authors: Weng Y,Zhang J,Tang X,Xie X,Chen G

    更新日期:2012-07-01 00:00:00

  • Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma.

    abstract::Low muscle mass (LMM) and low muscle density (LMD) are increasingly recognized as prognostic factors for survival in different malignancies. This study determined the association of LMM and LMD with survival in DLBCL (diffuse large B-cell lymphoma) patients. CT-based measurement of muscle was performed in 164 DLBCL pa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1737686

    authors: Rier HN,Kharagjitsing H,van Rosmalen J,van Vugt J,Westerweel PE,de Jongh E,Kock M,Levin MD

    更新日期:2020-07-01 00:00:00

  • Soluble Fas (APO-1/CD95) isoform in adult T-cell leukemia.

    abstract::Fas (APO-1/CD95) consists mainly of 2 isoforms, membrane-anchored (mFas) and soluble (sFas), both of which can mediate apoptosis through the Fas-signalling process, not only in normal but also in leukemia T-cells. This suggests that aberrant expression of either mFas or sFas may affect the natural history of T-cell ne...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109057967

    authors: Kamihira S,Yamada Y

    更新日期:2001-03-01 00:00:00

  • Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.

    abstract::The prognostic significance of rare BCR-ABL1 transcripts is uncertain in the tyrosine kinase inhibitor (TKI) era. In this retrospective study, 40 (1.7%) patients with rare BCR-ABL1 transcripts were identified from a cohort of 2331 chronic myeloid leukemia (CML) patients; 4 types of rare transcripts were identified, in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1607329

    authors: Xue M,Wang Q,Huo L,Wen L,Yang X,Wu Q,Pan J,Cen J,Ruan C,Wu D,Chen S

    更新日期:2019-12-01 00:00:00

  • N-ras gene point mutations in Brazilian acute myelogenous leukemia patients correlate with a poor prognosis.

    abstract::The frequency of ras gene mutations varies from 11 to 27% in AML populations from the United States and Europe but it seems that there is no study regarding the frequency of mutated N-ras gene in patients with AML in South America. In order to study the frequency of N-ras gene mutations (exons 1 and 2) in Brazilian pa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709039018

    authors: De Melo MB,Lorand-Metze I,Lima CS,Saad ST,Costa FF

    更新日期:1997-01-01 00:00:00

  • Hematological toxicities associated with amphotericin B formulations.

    abstract::Even though amphotericin B is associated with considerable hematological toxicity, this subject has been poorly studied. This retrospective cohort study assessed the incidence and predictors of hematological toxicity in patients treated with different amphotericin B formulations: amphotericin B deoxycholate (d-AmB), l...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1010080

    authors: Falci DR,da Rosa FB,Pasqualotto AC

    更新日期:2015-01-01 00:00:00

  • 2'-Deoxycoformycin for hepatosplenic gammadelta T-cell lymphoma.

    abstract::We describe a patient with unusually indolent hepatosplenic gammadelta T cell lymphoma characterised by severe lassitude and high fever. No significant responses were obtained to a range of chemotherapeutic and biological agents. 2'-deoxycoformycin (dCF), however, produced a dramatic and sustained clinical and histolo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109099342

    authors: Grigg AP

    更新日期:2001-08-01 00:00:00

  • Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.

    abstract::Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymph...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190210178

    authors: Perz J,Topaly J,Fruehauf S,Hensel M,Ho AD

    更新日期:2002-01-01 00:00:00

  • BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group.

    abstract::Patients with early stage favorable Hodgkin's disease who relapse after extended field radiotherapy have satisfactory results. We retrospectively analysed patients with relapsed HD after initial radiation therapy alone to determine treatment outcome and prognostic factors. Nine-hundred and forty five patients in local...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500178167

    authors: Rüffer JU,Ballova V,Glossmann J,Sieber M,Franklin J,Nogova L,Diehl V,Josting A,German Hodgkin Study Group.

    更新日期:2005-11-01 00:00:00

  • Acute myelogenous leukemia associated with a mediastinal tumor.

    abstract::We describe a 45-year-old female who developed acute myelogenous leukemia (AML) associated with a mediastinal mass. The patient achieved a complete remission accompanied by resolution of the mediastinal mass following intensive chemotherapy alone. A review of the literature disclosed ten AML patients with a mediastina...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309059583

    authors: Chubachi A,Miura I,Takahashi N,Nimura T,Imai H,Miura AB

    更新日期:1993-12-01 00:00:00